Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
levofloxacin (2156) 2156
science & technology (1869) 1869
humans (1828) 1828
life sciences & biomedicine (1789) 1789
male (1095) 1095
female (1002) 1002
anti-bacterial agents - therapeutic use (908) 908
pharmacology & pharmacy (810) 810
middle aged (806) 806
ofloxacin - therapeutic use (774) 774
adult (683) 683
infectious diseases (681) 681
biological and medical sciences (666) 666
medical sciences (643) 643
microbiology (643) 643
aged (633) 633
microbial sensitivity tests (526) 526
pharmacology. drug treatments (515) 515
antibiotics (504) 504
antibiotics. antiinfectious agents. antiparasitic agents (413) 413
treatment outcome (403) 403
levofloxacin - therapeutic use (401) 401
anti-bacterial agents - pharmacology (385) 385
antibacterial agents (356) 356
fluoroquinolones (340) 340
anti-infective agents - therapeutic use (303) 303
animals (294) 294
anti-bacterial agents - administration & dosage (293) 293
drug resistance (292) 292
drug therapy, combination (284) 284
ofloxacin - pharmacology (283) 283
aged, 80 and over (268) 268
ciprofloxacin (264) 264
ofloxacin - administration & dosage (249) 249
adolescent (245) 245
drug resistance, bacterial (231) 231
health aspects (223) 223
analysis (198) 198
bacteria (196) 196
pneumonia (193) 193
anti-bacterial agents - adverse effects (187) 187
antimicrobial agents (187) 187
ofloxacin - adverse effects (181) 181
drug therapy (178) 178
helicobacter pylori (177) 177
risk factors (175) 175
helicobacter infections - drug therapy (173) 173
drug resistance in microorganisms (171) 171
infections (169) 169
young adult (153) 153
amoxicillin (152) 152
care and treatment (152) 152
bacterial diseases (149) 149
ofloxacin - pharmacokinetics (148) 148
prospective studies (147) 147
anti-infective agents - pharmacology (141) 141
moxifloxacin (139) 139
bacterial infections and mycoses (138) 138
bacterial pneumonia (136) 136
community-acquired infections - drug therapy (132) 132
antibiotic resistance (129) 129
internal medicine (128) 128
fluoroquinolones - therapeutic use (125) 125
research (125) 125
anti-bacterial agents - pharmacokinetics (120) 120
abridged index medicus (118) 118
administration, oral (118) 118
clarithromycin (118) 118
gastroenterology & hepatology (112) 112
helicobacter pylori - drug effects (109) 109
dosage and administration (108) 108
retrospective studies (108) 108
patients (106) 106
general & internal medicine (105) 105
biochemical phenomena, metabolism, and nutrition (102) 102
quinolones (102) 102
medicine & public health (97) 97
amoxicillin - therapeutic use (95) 95
clarithromycin - therapeutic use (95) 95
anti-infective agents - administration & dosage (94) 94
immunology (92) 92
bacterial infections (91) 91
bacterial infections - drug therapy (87) 87
ciprofloxacin - therapeutic use (86) 86
infectious disease (84) 84
anti-infective agents - adverse effects (83) 83
streptococcus pneumoniae - drug effects (83) 83
anti-infective agents - pharmacokinetics (81) 81
clinical trials (81) 81
human bacterial diseases (81) 81
levofloxacin - administration & dosage (80) 80
medicine, general & internal (80) 80
antimicrobial resistance (79) 79
ciprofloxacin - pharmacology (79) 79
drug administration schedule (78) 78
antitubercular agents - therapeutic use (74) 74
azithromycin (74) 74
fluoroquinolones - pharmacology (74) 74
child (73) 73
medicine (73) 73
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2434) 2434
Spanish (50) 50
Japanese (46) 46
Russian (39) 39
Chinese (30) 30
French (29) 29
German (11) 11
Italian (10) 10
Portuguese (5) 5
Turkish (4) 4
Korean (3) 3
Dutch (2) 2
Hungarian (2) 2
Polish (2) 2
Bulgarian (1) 1
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
by Chey, William D and Leontiadis, Grigorios I and Howden, Colin W and Moss, Steven F
The American journal of gastroenterology, ISSN 0002-9270, 02/2017, Volume 112, Issue 2, pp. 212 - 238
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Salvage Therapy | Anti-Infective Agents - therapeutic use | Clarithromycin - therapeutic use | Bismuth - therapeutic use | Proton Pump Inhibitors - therapeutic use | Antacids - therapeutic use | Anti-Bacterial Agents - therapeutic use | Helicobacter pylori | Metronidazole - therapeutic use | Helicobacter Infections - drug therapy | Treatment Failure | Amoxicillin - therapeutic use | Levofloxacin - therapeutic use | Drug Therapy, Combination | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
by Ahmad, Nafees and Ahuja, Shama D and Akkerman, Onno W and Alffenaar, Jan-Willem C and Anderson, Laura F and Baghaei, Parvaneh and Bang, Didi and Barry, Pennan M and Bastos, Mayara L and Behera, Digamber and Benedetti, Andrea and Bisson, Gregory P and Boeree, Martin J and Bonnet, Maryline and Brode, Sarah K and Brust, James C M and Cai, Ying and Caumes, Eric and Cegielski, J Peter and Centis, Rosella and Chan, Pei-Chun and Chan, Edward D and Chang, Kwok-Chiu and Charles, Macarthur and Cirule, Andra and Dalcolmo, Margareth Pretti and D'Ambrosio, Lia and de Vries, Gerard and Dheda, Keertan and Esmail, Aliasgar and Flood, Jennifer and Fox, Gregory J and Fréchet-Jachym, Mathilde and Fregona, Geisa and Gayoso, Regina and Gegia, Medea and Gler, Maria Tarcela and Gu, Sue and Guglielmetti, Lorenzo and Holtz, Timothy H and Hughes, Jennifer and Isaakidis, Petros and Jarlsberg, Leah and Kempker, Russell R and Keshavjee, Salmaan and Khan, Faiz Ahmad and Kipiani, Maia and Koenig, Serena P and Koh, Won-Jung and Kritski, Afranio and Kuksa, Liga and Kvasnovsky, Charlotte L and Kwak, Nakwon and Lan, Zhiyi and Lange, Christoph and Laniado-Laborín, Rafael and Lee, Myungsun and Leimane, Vaira and Leung, Chi-Chiu and Leung, Eric Chung-Ching and Li, Pei Zhi and Lowenthal, Phil and Maciel, Ethel L and Marks, Suzanne M and Mase, Sundari and Mbuagbaw, Lawrence and Migliori, Giovanni B and Milanov, Vladimir and Miller, Ann C and Mitnick, Carole D and Modongo, Chawangwa and Mohr, Erika and Monedero, Ignacio and Nahid, Payam and Ndjeka, Norbert and O'Donnell, Max R and Padayatchi, Nesri and Palmero, Domingo and Pape, Jean William and Podewils, Laura J and Reynolds, Ian and Riekstina, Vija and Robert, Jérôme and Rodriguez, Maria and Seaworth, Barbara and Seung, Kwonjune J and Schnippel, Kathryn and Shim, Tae Sun and Singla, Rupak and Smith, Sarah E and Sotgiu, Giovanni and Sukhbaatar, Ganzaya and Tabarsi, Payam and Tiberi, Simon and Trajman, Anete and Trieu, Lisa and Udwadia, Zarir F and van der Werf, Tjip S and Veziris, Nicolas and Viiklepp, Piret and ... and The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017 and Collaborative Grp Meta-Analysis In and Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017
The Lancet (British edition), ISSN 0140-6736, 09/2018, Volume 392, Issue 10150, pp. 821 - 834
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Clofazimine - therapeutic use | Recurrence | Tuberculosis, Multidrug-Resistant - mortality | Linezolid - therapeutic use | Humans | Fluoroquinolones - therapeutic use | Tuberculosis, Pulmonary - drug therapy | Kanamycin - therapeutic use | Moxifloxacin | Capreomycin - therapeutic use | Amikacin - therapeutic use | Carbapenems - therapeutic use | Tuberculosis, Pulmonary - mortality | Diarylquinolines - therapeutic use | Treatment Failure | Antitubercular Agents - administration & dosage | Levofloxacin - therapeutic use | Drug Therapy, Combination | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Patient outcomes | Analysis | Drugs | Fluoroquinolones | Linezolid | Levofloxacin | Amikacin | Clinical trials | Systematic review | Drug resistance | Success | Clinical outcomes | Literature reviews | Heterogeneity | Kanamycin | Data analysis | Clofazimine | Adjustment | Mortality | Data processing | Thorax | Regression analysis | Disease control | Patients | Capreomycin | Meta-analysis | Studies | Multidrug resistant organisms | Infectious diseases | Adults | Respiration | Carbapenems | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Novel and effective therapeutic regimens for helicobacter pylori in an era of increasing antibiotic resistance
by Hu, Yi and Zhu, Yin and Lu, Nong-Hua
Frontiers in cellular and infection microbiology, ISSN 2235-2988, 05/2017, Volume 7, Issue MAY, pp. 168 - 168
Infection | Resistance | Treatment | Helicobacter pylori | Reinfection | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Prevalence | Humans | Helicobacter pylori - genetics | Helicobacter pylori - drug effects | Bismuth - therapeutic use | Furazolidone - therapeutic use | Anti-Bacterial Agents - therapeutic use | Metronidazole - therapeutic use | Helicobacter Infections - drug therapy | Levofloxacin - therapeutic use | Drug Resistance, Bacterial - drug effects | Drug Resistance, Bacterial - genetics | Pyrroles - therapeutic use | Helicobacter Infections - epidemiology | Tetracycline - therapeutic use | Clarithromycin - therapeutic use | Tetracycline Resistance | Proton Pump Inhibitors - therapeutic use | Drug Therapy, Combination - methods | Anti-Bacterial Agents - classification | Sulfonamides - therapeutic use | Amoxicillin - therapeutic use | Rifabutin - therapeutic use | Probiotics - therapeutic use | Mutation | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Index Medicus | treatment | infection | reinfection | resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
by Caminero, José A, Dr and Sotgiu, Giovanni, PhD and Zumla, Alimuddin, FRCP and Migliori, Giovanni Battista, MD
The Lancet infectious diseases, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Biological and medical sciences | Infectious diseases | Medical sciences | Bacterial diseases | Human bacterial diseases | Tuberculosis and atypical mycobacterial infections | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights